Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
AINU is set to accelerate its expansion footprint, enhance operational capabilities
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Marksans Pharma gets USFDA nod for acid reflux drug
Reinforcing commitment to ethical and sustainable growth
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
The agreement complements other PPAs for Sandoz production sites globally
Subscribe To Our Newsletter & Stay Updated